This article is more than 5 years old. Information may no longer be current.

Hologic receives FDA clearance for femur exam

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Hologic Inc. has received FDA clearance for its Single Energy Femur Exam on a dual energy X-ray absorptiometry platform for the assessment of features associated with atypical femur fractures.

According to a company press release, this capability assists clinicians in the assessment of potential atypical femur fractures in patients who have been on anti-resorptive treatments. Designed to produce a high resolution image of the entire femur with a very low effective radiation dose, the 15-second assessment can be performed at the time of a hip bone density scan with little or no patient repositioning and a minimal increase in exam time. The new assessment option will be offered on Hologic’s Horizon DXA platform.

“We developed our Single Energy Femur Exam in an effort to provide clinicians with the critical information needed to effectively manage patient care and improve fracture-related outcomes,” John Jenkins, vice president of marketing for specialty imaging products at Hologic, stated in the release.